A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera
Phase of Trial: Phase II
Latest Information Update: 27 Nov 2019
Price : $35 *
At a glance
- Drugs KRT 232 (Primary) ; Ruxolitinib
- Indications Polycythaemia vera
- Focus Therapeutic Use
- Sponsors Kartos Therapeutics
- 22 Nov 2019 Planned number of patients changed from 320 to 322.
- 06 Nov 2019 Trial design released in the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 22 Jul 2019 Planned number of patients changed from 295 to 320.